Carfilzomib: Uses, Mechanism & Side Effects
Carfilzomib is a proteasome inhibitor used to treat relapsed or refractory multiple myeloma. It selectively blocks enzyme complexes in cancer cells, triggering their programmed death.
Things worth knowing about "Carfilzomib"
Carfilzomib is a proteasome inhibitor used to treat relapsed or refractory multiple myeloma. It selectively blocks enzyme complexes in cancer cells, triggering their programmed death.
What is Carfilzomib?
Carfilzomib is a second-generation proteasome inhibitor used in the treatment of multiple myeloma, a malignant cancer of the plasma cells in the bone marrow. It is marketed under the brand name Kyprolis and has been approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for specific indications in patients with multiple myeloma.
Mechanism of Action
Carfilzomib works by selectively and irreversibly binding to the 20S proteasome, a key enzyme complex found in all human cells. The proteasome is responsible for breaking down damaged or unnecessary proteins. By blocking this degradation pathway, carfilzomib causes an accumulation of misfolded and damaged proteins inside tumour cells. This triggers apoptosis (programmed cell death) and inhibits the proliferation of malignant cells.
Compared to bortezomib, a first-generation proteasome inhibitor, carfilzomib acts more irreversibly and has a distinct side effect profile, particularly a lower risk of peripheral neuropathy (nerve damage in the hands and feet).
Indications
Carfilzomib is approved for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. It is typically administered in combination with other agents, such as:
- Carfilzomib + Lenalidomide + Dexamethasone (KRd regimen)
- Carfilzomib + Dexamethasone (Kd regimen)
- Carfilzomib + Daratumumab + Dexamethasone (KDd regimen)
Dosage and Administration
Carfilzomib is administered as an intravenous (IV) infusion, meaning it is delivered directly into a vein. Treatment is given in cycles, with the exact schedule (dose, frequency, duration) determined by the treating haematologist or oncologist. A typical schedule involves infusions on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Pre-medications such as dexamethasone and adequate hydration are usually given before infusions to help reduce the risk of side effects.
Side Effects
Like all cancer medications, carfilzomib can cause side effects, which may vary in severity depending on the individual and the combination regimen used.
Common Side Effects
- Fatigue and weakness
- Nausea and vomiting
- Anaemia (low red blood cell count)
- Thrombocytopenia (low platelet count)
- Shortness of breath (dyspnoea)
- Fever
Serious Side Effects
- Cardiac complications: Carfilzomib can cause heart failure, high blood pressure, or cardiac arrhythmias. Regular cardiac monitoring is required during treatment.
- Pulmonary embolism and thrombosis: An increased risk of blood clots exists, especially in combination regimens.
- Renal impairment: Kidney function must be monitored throughout treatment.
- Infusion reactions: Symptoms such as fever, chills, or dizziness may occur during or shortly after the infusion.
Contraindications and Precautions
Carfilzomib should not be used in patients with known hypersensitivity to the active substance. Special caution is required in patients with:
- Pre-existing heart disease
- Impaired kidney function
- Impaired liver function
- Pregnancy or breastfeeding (carfilzomib is contraindicated in these situations)
Regular monitoring of blood counts and organ function is essential throughout the course of therapy.
References
- European Medicines Agency (EMA): Kyprolis (carfilzomib) - Summary of Product Characteristics and European Public Assessment Report (EPAR). Available at: www.ema.europa.eu
- Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology. 2016;17(1):27-38.
- Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine. 2015;372(2):142-152.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryFRAX Score
Glucocorticoid-induced osteoporosis
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Carfilzomib